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BiomarkersIn the last decades the approach to cancer patient management has been deeply revolutionized. We are moving
from a “one-ﬁts-all” strategy to the “personalized medicine” based on the molecular characterization of the
tumor. In this new era it is becoming more and more clear that the monitoring of the disease is fundamental
for the success of the treatment, thus there is the need of new biomarker discovery. More precisely in the last
years the scientiﬁc community has started to use the term “liquid biopsy”. A liquid biopsy is a liquid biomarker
that can be easily isolated from many body ﬂuids (blood, saliva, urine, ascites, pleural effusion, etc.) and, as
well as a tissue biopsy, a representative of the tissue fromwhich it is spread. In this review we will focus our at-
tention on circulating tumor cells, circulating tumor DNA, exosomes and secretomes with the aim to underlie
their usefulness and potential application in a clinical setting for lung cancer patient management.
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t 10, 2650 Edegem, Belgium.1. Liquid biopsies: deﬁnition, usefulness and potential applications
The term liquid biopsy [1] was originally introduced to deﬁne circu-
lating tumor cells (CTCs). Currently it is also used for circulating tumor
DNA (ctDNA) [2,3] as well as for exosomes [4] (Fig. 1).
Liquid biopsy analysis is currently a rapidly expanding ﬁeld in trans-
lational cancer research as itmight be useful at different points of the di-
agnostic/therapeutic course of cancer patients. They may be used for
Fig. 1. An overview of liquid biopsy. CTCs are generated by the detachment of tumor cells from the neoplastic mass. The source of ctDNA still need to be investigated as it might be due to
necrotic or apoptotic events. Exosomes are actively secreted by cell and they can be deﬁned as “cellular biopsy”. Both CTC, ctDNA as well as exosomes can be isolated from plasma and be
used as a liquid biopsy of the disease.
540 C. Rolfo et al. / Biochimica et Biophysica Acta 1846 (2014) 539–546(a) early diagnosis, (b) estimation of the risk for metastatic relapse or
metastatic progression (prognostic information), (c) stratiﬁcation and
real-time monitoring of therapies, (d) identiﬁcation of therapeutic tar-
gets and resistance mechanisms (predictive information), and
(e) understanding metastasis development in cancer patients [1].
CTCs, ctDNA and exosomes are likely to contain a wider presentation
of genomic data from multiple metastatic sites, whereas mutations
present in a single biopsy or minor sub-clone may be missed [5]. More-
over, they may be obtained from almost all body ﬂuids (blood, serum,
plasma, urine, pleural effusion, ascites, etc.…).
CTCs are formed by cell detachment from the primary tumor mass,
determining themigration of tumor cells to secondary sites via the lym-
phatic and blood system. The presence of CTCs has been demonstrated
in the blood of patients with various solid tumors [6] and it has been as-
sociated with poor outcome in metastatic non-small cell lung cancer
(NSCLC) patients and small cell lung cancer (SCLC) as well as in other
tumors [7,8].
As aforementioned, CTC analysis might be useful for both, under-
standing themetastatic process and also formonitoring the disease dur-
ing treatment. In this regard there is a wide interest in the utility of
circulating nucleic acids (CNAs) and proteins as biomarkers of cancer.
Thus far, the majority of research has focused on circulating miRNAs,
mRNA and DNA (deﬁned also as cell-free DNA, cfDNA) due to their sta-
bility and easy isolation. Circulating miRNA has been extensively stud-
ied as a noninvasive biomarker for human disease. The signature
proﬁle of circulating miRNA has been shown to distinguish healthy
from diseased individuals [9]. Recently the other non-coding RNA(ncRNA), the long-non-coding RNA (lncRNA) is being investigated as a
novel biomarker in cancer patients [10].
cfDNA is released from both healthy and cancer cells but several
studies demonstrate that the tumor-released cfDNA (also identiﬁed as
circulating tumor DNA, ctDNA) is increased in cancer patients when
compared to healthy controls and its concentration further increases
with advanced disease [11]. The ctDNA can be used for molecular char-
acterization and its exosome-wide analysis could also complement the
current invasive biopsy approaches to identify mutations associated
with acquired drug resistance in advanced cancers [3] or for treatment
outcome monitoring.
Exosomes are small (40 to 100 nm)membrane derived vesicles that
are released extracellularly following the fusion ofmultivesicular bodies
or mature endosomes with the cellular membrane [12,13]. Exosomes
are released from normal, diseased, and neoplastic cells and are present
in the blood and other body ﬂuids [14]. They contain a variety of mole-
cules such as signal proteins and/or peptides, microRNAs, mRNAs, and
lipids [15]. Molecules contained within these small vesicles can there-
fore move through the bloodstream and reach distant sites, enabling
the exchange of “information and materials” between different sites.
mRNA-containing exosomes have been shown to be functional, as mu-
rine exosomes “taken up” by human cells resulted in the synthesis of
mouse proteins [15]. Because exosomes provide signals to distant
cells, they act as a nanoparticle-based communication system [16] and
could be fundamental for metastasis outcome [17]. Furthermoremetas-
tases harbor unique genomic characteristics that may not be detectable
in the corresponding primary tumor of the same patients. Thus, the
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standard practice in oncology) or, even the evaluation of tumor charac-
teristics based on the biopsy of the most accessible metastasis may not
reveal sufﬁcient information for treatment decisions [18].
Recently, Thakur et al. have demonstrated that exosomes also con-
tain double-stranded DNA, deﬁned as exoDNA, that could be character-
ized, aswell. In the same paper the authors also assessed that exoDNA is
representative for the whole genomic DNA and this ﬁnding strengthens
the translational potential of exosomes as circulating cancer biomarkers
[19].
The “secretome” is referred to as the rich, complex set of molecules
secreted from living cells. More loosely the term also includesmolecules
shed from the surface of living cells. Secretome proteins play a key role
in cell signaling, communication and migration [20]. The current
protein-based serum biomarkers in lung cancer clinical practice include
carcinoembryonic antigen (CEA), cytokeratin 19 fragment (CYFRA 21-
1), tissue polypeptide antigen (TPA), pro-gastrin releasing peptide
(ProGRP), neuron-speciﬁc enolase (NSE) and tumor M2 pyruvate ki-
nase [21].
2. Clinical perspectives and research opportunities from liquid
biopsy in lung cancer
Cancer is not a “molecularly stable” disease, instead it is character-
ized by a high heterogeneity. In particular for lung cancer it is known
that many patients with advanced EGFR-mutated or ALK-rearranged tu-
mors do beneﬁt from treatment with speciﬁc tyrosine kinase inhibitors
(TKIs, such as geﬁtinib, erlotinib, crizotinib and ceritinib) [22–26]. Un-
fortunately the length of disease control is notoriously short due to
the acquisition of resistance mechanisms. EGFR TKI-acquired resistance
is mostly (50–60%) due to a pointmutation in exon 20 (T790M) and oc-
casionally (5–10%) due to c-MET ampliﬁcation, among others [27,28].
Thus primary tumor and metastases might be molecularly different.
Furthermore, metastasis is the leading cause of death in cancer patients
while early-stage disease is starting to be considered curable, or, at least,
is characterized by a remarkably high survival rate. A detailed character-
ization of metastases is therefore needed to improve patient outcome
even in advanced-disease stages. The main issue in characterizing me-
tastasis is its intrinsic nature, since it is often tricky and difﬁcult forFig. 2. Clinical application of CTC and ctDNA analyses in cancer patients. Modiﬁcations of CTC a
ation CTC and ctDNA levels dramatically drop down according also to tumor growth decrease.
relapse detection than CT/PET scan analysis.sampling. Liquid biopsies offer the chance to investigate primary
tumor and metastasis through a non-invasive and simple blood tests.
Another interesting feature of liquid biopsy, mostly of ctDNA analysis,
is the opportunity to study “tumor dormancy” phenomenon. Cell-free
DNA might offer the opportunity to monitor patients with no clinically
detectable disease after surgery and standard therapy. It has been dem-
onstrated that T790M mutations are detectable in the blood before ra-
diological and symptomatic relapse [3,29,30]. Thus in the near future
disease monitoring might also be integrated with ctDNA testing and
CTC molecular characterization (Fig. 2).
3. CTCs, ctDNA, exosomes and secretomes in NSCLC: what's new?
3.1. Circulating tumor cells (CTCs): clinical data in NSCLC and SCLC
Since they were ﬁrst described by Thomas Ashworth in 1869 [31],
the presence of circulating tumor cells has been suggested to be a char-
acteristic of cancer by various early studies [32]. CTCs are cancer cells re-
leased from tumors into the bloodstream. Over the past years CTCs'
presence has been associated with worse prognosis in several major
cancer types, including breast, prostate, colorectal and lung cancer.
Through a proposed process known as the epithelial–mesenchymal
transition (EMT), epithelial cells of solid tumors undergo cellular chang-
es that enable them to escape their structural conﬁnes via increasedmo-
bility and invasiveness, to enter into the bloodstream, and to adhere to
endothelial cells and give birth to distant metastases [33,34].
Thus, isolation and characterization of CTCs represent a very attrac-
tive challenge, as they may comprise both the phenotypic and genetic
compositions of the primary tumors and potentially serve as a liquid bi-
opsy for any metastatic or non-metastatic tumors. The analysis of CTCs
offers the possibility to surrogately evaluate metastasis in real-time
and to investigate the actual “molecular condition” of the disease. For
example, an EGFR activating mutation can be identiﬁed in CTCs and in-
terestingly CTCs offer the opportunity to monitor the appearance of
drug resistance mutations (as T790M for TKI resistance) [35,36].
The enumeration of CTCs is considered relevant as a surrogatemark-
er for tumor growth as well as for deﬁning tumor aggressiveness. In this
regard, the decrease in the number of CTCs during the treatment has
been associated with radiographic tumor response; on the contrary annd ctDNA levels in plasma during disease progression. After diagnosis and treatment initi-
At relapse both CTC and ctDNA levels increase and are more sensitive (ctDNA N CTCs) in
Table 2
ctDNA analysis.
Methods Sensitivity Speciﬁcity
Quantitative
analysis
⁎qPCR
Ampliﬁcation of ALU sequences,
LINE gene, β-globin, β-actin
High Low
Qualitative analysis
(based on DNA
speciﬁc mutation)
Sanger sequencing Very low High
Pyrosequencing Low Low
⁎NGS Low High
⁎ARMS Low High
⁎BEAMing High High
Digital PCR High High
⁎TAM-Seq High High
⁎ qPCR: quantitative polymerase chain reaction (PCR); NGS: Next Generation Se-
quencing; ARMS: ampliﬁcation refractory mutation system; BEAMing: beads, emul-
sion, ampliﬁcation and magnetic; TAM-Seq: tagged-amplicon deep sequencing.
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more, in NSCLC patients the total count of CTCs before chemotherapy
initiation is associated with staging (higher detectable number of cells
in stage IV patients) and the progression-free survival (PFS) and overall
survival (OS) seem to be correlated to CTC count. In the study from
Krebs G. et al., PFS and OS were higher among NSCLC patients with
fewer than ﬁve CTCs per 7.5 ml of blood when compared to patients
with ﬁve or more CTCs [7] and they conclude that CTC number is the
strongest predictor of OS. In addition, the presence of circulating cells
is associated with a signiﬁcantly higher risk of lymph node metastasis
but not with tumor histology in NSCLC [37]. Recently it has been proved
the prognostic value of CTC enumeration in patients with SCLC [8,38].
The reduction of CTC count higher than 89% after one chemotherapy
cycle improves prognostic accuracy and is associated with lower risk
of death. Furthermore CTC count is strongly associatedwith the number
of metastatic sites [39]. In Table 4 are listed themajor clinical investiga-
tions of liquid biopsy in lung cancer.
CTCs might be prognostic markers in cancer patients and, in the fu-
ture, therapy decision should also be made taking into account CTC
analysis, especially for the selection of those patients at a higher risk
of relapse who might beneﬁt from adjuvant therapies.
Currently, there is only one technology approved for CTC enrich-
ment and enumeration. This technique has been used in various clin-
ical trials (breast, prostate and colon cancers) to establish in which
subset of patient CTC count above a known threshold might be
used as a prognostic marker and a predictor of patient outcome
[40–42]. Based on these clinical trials, the US Food and Drug Admin-
istration (FDA) licensed the CellSearch® technology (Veridex, LLC,
Raritan, NJ, USA) for CTC analysis in clinical practice. This system
uses immunomagnetic puriﬁcation with antibodies against epitheli-
al cell adhesion molecule (EpCAM) from peripheral blood. The spec-
iﬁcity of CellSearch® isolation is only based on EpCAM expression on
CTC surface. Consequently, CTCs with low or absent expression of
EpCAM are easily missed. Thus, tumor cells that have undergone
EMT, and which are probably the most aggressive, are not detectable
with CellSearch® technology. There is an increasing number of pa-
pers that, by using alternative detection technologies on the basis
of EpCAM or other antigens, have demonstrated an apparent greater
sensitivity than CellSearch® [43,44] but further studies in the con-
text of larger clinical studies are warranted. In Table 1 are shown
themost promising and interesting new techniques for CTC isolation.
While all these newmethods of separation provide the advantage of
enriching for viable CTCs, which may be collected and stained for
cytopathological analysis or subjected to RNAorDNA analyses, the tech-
nologies still need to be improved because they are quite elementary
and imprecise (especially density gradient and ﬁltration methods).
Thus the main issue is to strike a balance between lower number of
CTCs but high purity and greater number of CTCs but reduced purity.Table 1
CTC enrichment and isolation methods: A comparison of the available techniques.
Enrichment methods Product Cell
viability
Antibody-
based
Sp
Yes No Yes No Lo
Biological properties
Immunomagnetic bead CellSearch System x x
Magsweeper x x
CTC-chip x x
GILUPI Nanodetector x x
Physical properties
Density gradient centrifugation Immunorosettes x x x
Filtration ISET x x x
CellSieve x x x
Dielectrophoresis APOstream x x x
DEPArray x x x3.2. Circulating tumor DNA (ctDNA): quantitative and qualitative
alterations of ctDNA in lung cancer
Currently the evaluation of speciﬁc predictive biomarkers is manda-
tory for a proper treatment of NSCLC patients according to the molecu-
lar characterization of the disease. Indeed, the EGFR mutation status
assessment inNSCLC patients is deﬁnitely embedded in clinical practice.
Nonetheless, molecular proﬁling can be difﬁcult due to the very small
amount of tumor tissue available for the analysis (as most are obtained
by ﬁne needle aspiration procedures). Many investigators have tried to
solve this problem, leading to the development of more sensitive tech-
niques to detect EGFR mutations [45,46]. ctDNA testing might be an
ideal solution.
ctDNA originates fromboth healthy and tumor cells [47,48] andmay
have broad clinical applications because it is non-invasive, convenient
and ctDNA based assays can be performed repeatedly [49]. DNA re-
leased from necrotic malignant cells varies in size, whereas DNA re-
leased from apoptotic cells is uniformly truncated into 185- to 200-bp
fragments. Because the main source of free circulating DNA in healthy
individuals is from apoptotic cells, a preponderance of longer DNA frag-
ments could be a marker for malignant tumor detection [50,51]. Cell-
free DNA levels have been demonstrated to be higher in cancer patients
compared with healthy controls [11,52–54]
ctDNA can also be used formutational analysis and there are already
several proof-of-concept papers on the potential of ctDNA testing in the
management of NSCLC patients. Thewhole exome sequencing of ctDNA
through Next Generation Sequencing (NGS) has been demonstrated to
provide relevant information about the molecular status of the tumor.
Recently Murtaza et al. have performed whole exome sequencing of
plasma DNA of six patients with advanced cancers (two with breast
cancer, three with ovarian cancer and one with NSCLC). Interestingly
in NSCLC patients, the analysis of the EGFR gene in cfDNA has showneciﬁcity Sensitivity Downstream apllication References
w High Low High
x x CTCs enumeration and analysis [1]
x x Molecular analysis [2]
x x CTCs enumeration and analysis [3]
x x CTCs enumeration and analysis [4]
x CTCs enumeration and molecular analysis [5]
x CTCs isolation and molecular analysis [6]
x CTCs isolation and molecular analysis
x CTCs isolation and molecular analysis [7]
x CTCs isolation and molecular analysis [8]
Table 3
Exosomes isolation methods.
Isolation methods Description Advantages Disadvantages References
Differential
centrifugation
It consists of multiple steps:
- Depletion of cells, cell debris and large apo-
ptotic bodies by low-speed centrifugation
(300 ×g 10′)
- Larger vesicles are collected after a higher
speed spin (10,000 ×g)
- Smaller vesicles (exosomes) are then
pelleted at high speed (100,000–
120,000 ×g). Ultracentrifugation is often
performed in combination with sucrose
density gradients or sucrose cushions to
ﬂoat the relatively low-density exosomes.
- Is considered the gold standard
method
- Is widely used to isolate vesicles
from body ﬂuids and conditioned
medium
- This procedure cannot achieve absolute
separation by size because sedimenta-
tion also depends on the density and
content of vesicles.
- The pellet could contain proteins, com-
plexes, lipoproteins and other contami-
nants.
- Extremely cumbersome process (4-5 h).
[9–11]
Size exclusion Cell fragments and larger vesicles can be
excluded by a ﬁltration step with a 0.8 μm pore
size ﬁlter. To collect smaller vesicles
(exosomes), a 0.2 μm pore size ﬁlter can be
used.
- Allow the separation of vesicles
based on size
- Isolation of a vesicle population
homogeneous in size
- Forcing vesicles through a ﬁlter could
cause their deformation or breakup.
- Vesicles could be trapped in micro-
pores.
[9]
Immunoafﬁnity
isolation
The presence of characteristic surface proteins
on different vesicle populations, allows the
speciﬁc isolation of desired vesicles through the
immunoafﬁnity isolation, in which antibodies to
surface proteins (CD9, CD63, CD81, MHC) are
used to select desired vesicles population.
High speciﬁcity and characterization of
vesicles
- Lower yields because some markers are
not recognized on all vesicles.
- The obtained population cannot be used
for further functional assays.
- It is not suited for isolation of large
amount of vesicles.
[12–14]
Microﬂuidic devices Micro- and nano-ﬂuidic methods separate
nanoparticles based on physical properties.
- Reduce material costs and samples
volume
- Single step capture
The application of these methods to
biological ﬂuids has not yet been well
described.
[15,16]
Polymeric
precipitation
(ExoQuick)
Volume-excluding polymers, such us PEGs, are
capable of differentially precipitating vesicles
thereby allowing exosome isolation by low-
speed centrifugation.
- Technically easy
- Require small amount of sample
- Short time of isolation
- high yield of RNA
- The purity of the isolated material is not
certain.
- High contamination from lipoproteins.
[17,18]
543C. Rolfo et al. / Biochimica et Biophysica Acta 1846 (2014) 539–546the occurrence of the resistancemutation T790Mat progression, but not
at the time of treatment initiation [3]. cfDNA quantiﬁcation may also be
associated to tumor burden estimated by Positron Emission Tomogra-
phy/Computerized Tomography (PET/CT) [55]. The evaluation of the
KRAS mutation in cfDNA from NSCLC individuals has demonstrated
that patients with a detectable plasma-KRASmutation had a signiﬁcant-
ly shorter OS and PFS compared to patients showing wild type (WT)
plasma-KRAS. Thus, the detection of KRAS mutations in plasma may
earn a prognostic as well as a predictive value [56].
Despite the promising results obtained in support of the feasibility of
ctDNA testing there is still a lack of widely accepted and approved
methodologies for ctDNA analysis. To successfully detect the presence
of ctDNA in plasma or serum, a suitablemethodology needs to be select-
ed. This consists of several essential steps: 1) processing collected blood
while avoiding the rupture of blood cell membranes and subsequent
plasma contamination with DNA derived from the blood cells nuclei;
2) select the most appropriate method to gain a sufﬁcient amount of
quality DNA for further analysis; 3) detection of ctDNA (through real-
time PCR or digital PCR and NGS) [57]. cfDNA detection can be per-
formed through two main methodologies: quantitative analysis and
analysis based on DNA-speciﬁc mutation detection. The ﬁrst one allows
DNA quantiﬁcation of cfDNA including tumor and non-tumor derived
DNA. This technique is based on the ampliﬁcation of ALU sequences or
other speciﬁc markers (β-globin; β-actin; hTERT; etc.…) and detection
through real-time PCR [58–61]. DNA-speciﬁc mutation analysis in
cfDNA is challenging due to the presence of high levels of wild-type
DNA originating either from apoptotic or necrotic tissues. Nevertheless
mutational studies can be performed using several methods, beginning
from sequencing with limited sensitivity, through methods based on
conformational changes and electrophoresis (e.g., denaturing capillary
electrophoresis, DCE), alternatively increasing the mutant fraction by
mutant-enriched PCR (ME-PCR), and opting for a dedicated approach
such as “BEAMing” (beads, emulsion, ampliﬁcation, and magnetics),
digital PCR, or single-molecule sequencing [57]. In Table 2 there is anoverviewof themain techniques used for ctDNAanalysis and their char-
acteristics in terms of sensitivity and speciﬁcity.
3.3. Exosome and miRNA in NSCLC
Exosomes are small membrane vesicles of endocytic origin andwere
initially isolated from the peripheral circulation of patients with cancer
in 1979 [62,63]. Exosomes appear to play a central role in cell-to-cell
communication by a direct activation of surface-expressed ligands or
by transferring molecules between cells. Exosomes can have a bimodal
role in cancer: they can either manipulate the local and systemic envi-
ronment allowing cancer growth and dissemination or modulate the
immune system to elicit or suppress an anti-tumor response [64,65].
Exosomes are rich in DNA fragments, proteins, mRNA and microRNA
(miRNA). Interestingly enough, exosomal RNA has been shown to de-
termine horizontal transfer of genetic information between cells [66].
In recent years, studies on exosome's prognostic and predictive value
in NSCLC have evolved and new evidences have emphasized their po-
tentiality in clinical practice. Biological molecules (protein, RNA and
miRNA) well protected by a lipid bilayer membrane that confers high
degree of stability, are contained in exosomes and can be isolated and
analyzed quite simply. The genome-wide expression proﬁling of
miRNAs has been shown to be signiﬁcantly different among primary
lung cancers and corresponding noncancerous lung tissues and thus
has shown to have a potential role as a diagnostic marker. An overex-
pression of 12 speciﬁc miRNAs (hsa-miR-17-3p, hsa-miR-21, hsa-miR-
106a, hsa-miR-146, hsa-miR-155, hsa-miR-191, hsa-miR-192, hsa-
miR-203, hsa-miR-205, hsa-miR-210, hsa-miR-212, and hsa-miR-214)
has been revealed comparing themiRNA expression proﬁle of lung can-
cer samples with normal lung tissues [67]. On the basis of this genome-
wide expression proﬁle, Rabinowits et al. [68] investigated the role of
exosomal miRNA as a diagnostic marker for lung cancer. Comparisons
between peripheral circulation miRNA-derived exosomes and miRNA-
derived tumors indicated that the miRNA signatures were not
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miRNAs were elevated in NSCLC and that the associations of these 12
were mirrored in the circulating exosomes [68]. Thus, from these re-
sults, it is suggested that exosome miRNA proﬁling can be performed
in the absence of tumor tissue and accurately reﬂect the tumor's proﬁle.
Exosomal tumor miRNAs have been shown to also educate selected
host tissues toward a prometastatic phenotype [69]. This peculiar
exosome featuremakes them an attractive and interesting target to po-
tentially inhibit the metastatization process.
For translational and clinical practice applications of exosome anal-
ysis several features are required: (1) rapidity, exosome-speciﬁc extrac-
tion, (2) simple, effective biomarker release from exosomes, and
(3) highly sensitive, speciﬁc detection of endogenous bio-molecules
[70]. Conventional exosome diagnostic methods comprise a two-step
procedure, including exosome extraction from body ﬂuids, followed
by the speciﬁc detection of harbored biomarkers that are associated
with a variety of diseases [71]. Despite a rapidly growing number of re-
search studies, there is still rather limited and superﬁcial information
available regarding RNA content of exosomes [72]. Moreover, certain
reports contain a number of contradictions and this is due to the lack
of standardized techniques, protocols, and workﬂows for isolation of
exosomes and downstream analysis of their constituents. Currently,
the most commonly used approach for exosomes isolation is based on
ultracentrifugation [73]. However, this technique is burdened by sever-
al problems: the long processing time, the fact that the process is
unreliable, unreproducible and not completely selective for tumor
exosomes. Furthermore, the abundance of exosomes of different cellu-
lar origins and different compositions in peripheral blood makes a fur-
ther enrichment of the relevant biomarkers a necessary step when
considering exosomes for diagnostic or companion diagnostic pur-
poses. In Table 3 the different techniques used to isolate exosomes for
prognostic and diagnostic use are summarized.
A viable alternative in distinguishing the different subpopulations of
extracellular vesicles (apoptotic bodies, microvesicles and exosomes)
might be RNA proﬁling. In fact, according to RNA proﬁling, ribosomal
RNA (rRNA) is primarily detectable in apoptotic bodies and smaller
RNAs without prominent rRNA peaks in exosomes. In contrast,
microvesicles contain little or no RNA. The different vesicle pellets
show highly different distributions of size, shape and electron density
when analyzed by transmission electron microscopy, each having typi-
cal characteristics [74]. Currently, the characterization and concentra-
tion of nanoparticles in liquid can be obtained through the
NanoSight™ platform [75]. Also other techniques are available for
exosome identiﬁcation and characterization: electron microscopy,
ﬂow cytometry and Western blot [76].
Recently the increased application of proteomic technologies has
signiﬁcantly contributed to a deeper understanding of the protein pro-
ﬁles of exosomes from a wide variety of cultured cells and body ﬂuids
(such as plasma, urine and malignant effusions) [77]. A part of these
studies is speciﬁcally focused on tumor derived exosomes (TDE) and
the obtained data are providing new knowledge not only for under-
standing more about their role in the regulation of tumor microenvi-
ronment but also for their potential use as disease markers. All
proteomics data acquired to date demonstrate that TDEs express a dis-
crete set of proteins speciﬁcally related to the tumor phenotype and in-
volved in cell proliferation, antigen presentation, signal transduction,
migration, invasion and angiogenesis, supporting the notion that
exosomes may play a crucial role in regulating the changes of tumor
niche and in driving tumor progression. Several of these proteins can
be used for prognostic and diagnostic purposes. Recently, the ﬁrst glob-
al proteomic analysis of highly puriﬁed exosomes derived from human
NSCLC malignant pleural effusion has been reported. Using nanoLC–
MS/MS following 1D SDS-PAGE separation, researchers have identiﬁed
pathologically relevant proteins and potential diagnostic makers for
NSCLC, including lung-enriched surface antigens and proteins related
to EGFR signaling. These ﬁndings provide new insight into themultiple
545C. Rolfo et al. / Biochimica et Biophysica Acta 1846 (2014) 539–546functions of exosomes in cancer progression andwill aid in the develop-
ment of novel diagnostic tools for NSCLC [78].
3.4. Secretome in lung cancer
The term “secretome”was introduced by Tjalsma et al. in a study
of the secreted proteins in Bacillus subtilis [79] and includes proteins
released by a cell, tissue or organism through different secretion
mechanisms [80]. The cancer secretome was ﬁrst mentioned in
2006 [81]. Secreted proteins participate in various physiological pro-
cesses such as immune defense, blood coagulation and cell signaling
and also play crucial roles in pathological processes including cancer
angiogenesis, differentiation, invasion and metastasis. Proximal bio-
logical ﬂuids (e.g. ascites ﬂuid of ovarian cancer or pleural effusion of
lung cancer) that are in contact with the tumormay be enrichedwith
proteins secreted or shed by cancer cells. Such proteins could enter the
circulation and be detected in body ﬂuids such as blood and urine [20].
The malignant pleural effusion is a clinical complication that occurs rel-
atively often in NSLC. This malignant effusion has been analyzed to
identify useful biomarkers in lung cancer and recently a “secretomic-
proﬁle” of malignant pleural effusion from lung adenocarcinoma pa-
tients has been proposed. Researchers were able to identify 482 non-
redundant proteins. Through subsequent in vitro analyses, 4 potential
protein biomarkers signiﬁcantly associated with malignancy were iso-
lated. These ﬁndings collectively suggest that the malignant pleural ef-
fusion proteome (secretome) from adenocarcinoma NSCLC provides a
useful data set for malignancy biomarker research [82]. Several groups
have studied the proteomic proﬁle of secreted proteins derived from
NSCLC cell lines [83,84] and have tried to translate the obtained results
into clinical practice. Despite the fact that the interest in secretome
analysis of NSCLC patients is progressively growing, there is still a gap
between in vitro secretome testing and clinical applications.
4. Conclusion
Our understanding and knowledge of cancer have changed dramat-
ically over the last 30 years. The discovery of oncogene addiction has
paved the way for the development of “intelligent” drugs, able to target
only cancer cells. The introduction of molecular biomarkers in clinical
practice has changed the natural history of many tumors (c-KIT and
PDGFRA in GIST, EGFR in lung cancer, BRAF inmelanoma and KRAS in co-
lorectal cancer) and the molecular characterization of cancer through
NGS still holds many surprises. Nevertheless, the major limitation of
these drugs is the rise of resistance mechanisms that impair and slow
down the development of genotype-directed therapy in solid tumors.
Tumor cells never reach a steady state. They are continuously
changing and they acquire new mutations to survive in an adverse
environment. The “dark side” of a targeted agent is due to the selec-
tive pressure that favors the selection of most aggressive cells. These
cells are likely the ones that escape from the primary tumors and col-
onize distant districts causing metastasis onset. Since these ﬁndings,
metastatic cells are thought to be a clone of the primary tumors with
a more aggressive behavior. It is now becoming increasingly clear
that metastasis and tumors are extremely heterogeneous and there-
fore, metastatic disease has been proposed as a different condition.
From these considerations it is clear how important is the character-
ization of the new lesion through a re-biopsy. Unfortunately re-
biopsy is not always feasible due to many reasons (e.g. comorbidity
of the patients, the lack of a safe access to the lesion). In this context,
liquid biopsies could be an effective solution. Recently, Oxnard et al.
[30] have demonstrated that cell-free plasma DNA is suitable for
monitoring treatment response but also for the early detection of ac-
quired resistance mechanisms (e.g. T790M in NSCLC). These and
other studies are setting the basis for the development of cfDNA as
a new and non-invasive biomarker that can be used routinely as pre-
dictive biomarker for targeted therapies.The value of CTC analysis is, at present, mainly correlated to progno-
sis but there is an increasing interest in the development of new tech-
niques for their molecular characterization. CTCs are cells that detach
from the primary tumors and migrate through the bloodstream. It is
not fully understood whether CTCs are the only cause of metastasis
but it is well known from clinical studies that their count is proportional
to a poorer prognosis in various tumor types. The prognostic value of
CTCs is then almostwidely acceptedwhile there is still the need of effort
for their molecular characterization.
Exosome analysis in cancer is a new ﬁeld and there are still many
questions about their function. Exosomes can be considered as “op-
erating/active secretions” of cancer cells and, as secretome, they
might be representative for the functional status of tumor cells. So,
these microvesicles are more than simple exophytic budding of cell
membrane. Thus, the analysis of molecules contained in exosomes
can provide additional information about the tumor biology.
These new insights are paving the way for a deep changing in the
approach of patients' management. Analysis based on tissue biopsies
will be complemented with the information obtained from CTCs,
ctDNA and exosome characterization. These information, together
with the one obtained from the imaging analysis, will probably
guide treatment decision andwill improve the outcome for lung can-
cer patients. Another important aspect of liquid biopsy is that, due to
their non-invasive nature, they might be applied also in a diagnostic
setting. It is well known that lung cancer is an insidious disease that
most frequently occurs in advanced stage. This is mainly due to the
lack of a screening test for the disease and liquid biopsy can be a use-
ful tool for diagnostic purpose.
Nevertheless there are still several limitations for the introduction of
liquid biopsy in a clinical setting. Except for CTC enumeration with the
Veridex system (FDA-approved), there are no validated techniques
both for cfDNA and exosome analysis. cfDNA evaluation is not yet stan-
dardized and, for instance, the optimal sampling specimen (plasma or
serum) is not yet known. Moreover among laboratories that work
with ctDNA there are not yet optimized, standardized and widely
approved procedures for blood collection and downstream analysis.
Following this consideration, the increasing effort in liquid biopsy
development is understandable, even if the road is still long and wind-
ing, but hopes are high to see them included in clinical practice.References
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